GOVERNMENT OF INDIA
CHEMICALS AND FERTILIZERS
LOK SABHA

UNSTARRED QUESTION NO:4511
ANSWERED ON:20.12.2012
PRODUCTION OF DRUGS
Alagiri Shri S. ;Singh Rajkumari Ratna

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) the production of drugs by pharmaceutical Public Sector Enterprises during each of the last three years and the current year, company-wise;

(b) the share of their drugs in the total production of drugs in the country during the said period;

(c) whether the private drug manufacturing companies are charging higher prices of their products due to low production by Public Sector Enterprises;

(d) if so, the details thereof; and

(e) the steps being taken by the Government in this regard?

Answer

MINISTER OF STATE (INDEPENDENT CHARGE) OF THE MINISTRY OF STATISTICS AND PROGRAMME IMPLEMENTATION AND MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI SRIKANT KUMAR JENA)

(a) The production value of drugs by pharmaceutical Public Sector Enterprises during each of the last three years and the current year, company-wise is as under:

(Rs. In crore)

Pharmaceutical Public Sector Enterprises [CPSEs]	Rajasthan Drugs & Pharmaceuticals Ltd. (RDPL)	Indian Drugs & Pharmaceuticals Ltd. (IDPL)	Hindustan Antibiotics Ltd. (HAL)	Bengal Chemicals & Pharmaceuticals Ltd. (BCPL)	Karnataka Antibiotics & Pharmaceuticals Ltd. (KAPL)	Total production of all CPSEs
2009-2010	82.88	108.12	123.15	40.67	218.75	573.57
2010-2011	83.80	55.24	84.92	37.51	239.27	500.74
2011-2012	82.26	50.76	53.85	29.09	251.00	466.96
2012-2013	35.70 (Upto Oct. 2012)	34.02 (Upto Nov. 2012)	31.91 (Upto Nov.2012)	04.91 (Upto Oct. 2012)	143.36 (Upto Oct. 2012)	249.90

(b) The share of Central Pharmaceutical Public Sector Enterprises` [CPSEs] drugs in the total production of drugs in the country during the said period is as under:-

S.No.	Year	Total production of Indian Pharmaceutical Industry (Rs. In crore)	Total production of CPSEs	Share in %
1	2009-2010	106209.00	573.57	0.54%
2	2010-2011	119075.60	500.27	0.42%
3	2011-2012	Data not available	466.96	â€”
4	2012-2013	Data not available	249.90	â€”

upto October/November-2012

(c), (d)&(e): There is a considerable difference in the prices of branded medicines manufactured by private manufacturers and sold in open market as compared to the prices being charged in the generic version of the same salt/molecule being manufactured and supplied by Phanma CPSEs. A comparative statement of some of the medicines, which are commonly used, is illustrated as under

S.No.	Generic name	Pack size	Jan Aushadhi (Rs.)	Leading brand	Leading Brand name	Therapeutic segment
1.	Alprazolam 0.25 mg	10 tab	2.60	13.60	Triaka 0.25 mg.	Anxiolytic
2.	Atenolol 50 mg	10 tab	5.00	33.48	Aten 50 mg	Cardio vascular
3.	Losartan 50 mg	10 tab	9.40	57.30	Losar 50 mg	Cardio vascular
4.	Levocetrizine 5mg	10 tab	5.80	41.30	Le-Zyncet 5mg	Anti-allergic

The prices of 74 bulk Drugs, specified in the First Schedule of Drug Price Control Order [DPCO], 1995 and the formulations containing any of these scheduled drugs are fixed/revised by the National Pharmaceuticals Pricing Authority [NPPA]. Under the provisions of DPCO, 95, no person is authorised to sell any scheduled formulation (medicine) to a consumer at a price exceeding the price notified/approved by the NPPA/Government. In respect of non-scheduled formulations, for which prices are not fixed under DPCO, 1995, NPPA monitors their prices on a regular basis, not linked with production figure. As a part of price-monitoring activity. NPPA regularly examines the movement in prices of non-scheduled formulations. The monthly reports of IMS Health and the information furnished by individual manufacturers are utilized for the purpose of monitoring prices of non-scheduled formulations. Wherever a price increase beyond 10% per annum is noticed, the manufacturer is asked to bring down the price voluntarily failing which, subject to prescribed conditions, action is initiated under paragraph 10 (b) of DPCO, 1995 for fixing the price of formulation in public interest.